Leptomeningeal Disease Recruiting Phase 2 Trials for Tucatinib (DB11652)

Also known as: Metastases to meninges / Malignant meningitis / Meningeal Carcinomatosis

IndicationStatusPhase
DBCOND0075962 (Leptomeningeal Disease)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03501979Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDTreatment